Figure 5: In vivo neutralization of IL-25 activity can effectively invalidate the anti-metastatic activity of Q2-3.
From: Induction of IL-25 secretion from tumour-associated fibroblasts suppresses mammary tumour metastasis
(a) Representative bioluminescent images of tumour-resected mice (n=8 per group) after in vivo treatment with PBS (0.1% DMSO in saline), Q2-3 (100 μg kg−1; 3 injections per week), anti-mouse IL-25 Ab (100 μg per mice; 2 injections per week), Q2-3+IL-25 Ab, or Q2-3+isotype IgG, at 3 weeks post tumour resection. The label ‘D’ in the photograph denotes the mice died before 3 weeks post tumour resection. (b) Quantification of tumour metastasis by measuring luciferase activity photons s−1 cm−2 sr−1 in mice, as revealed along the indicated time course (12 weeks). (c) Survival of test mice after different treatments. NS, no significant difference between the ‘Q2-3’ and ‘Q2-3+Anti-IgG’ groups. **P<0.01, was obtained between the ‘Q2-3’ and ‘Q2-3+Anti-IL-25’ groups (Kaplan–Meier results were analysed by log-rank test). Similar results were obtained from two independent experiments.
